NCT05113537View on ClinicalTrials.gov

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2027

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Castration-resistant Prostate CarcinomaMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Abemaciclib

Given Orally

DRUG

Lutetium Lu 177-PSMA-617

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

lead

Vadim S Koshkin

OTHER